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Abstract
Prions are the infectious agents causing transmissible spongiform encephalopathies
(TSE), progressive, inexorably lethal neurological diseases. Antibodies targeting the globu-
lar domain (GD) of the cellular prion protein PrPC trigger a neurotoxic syndrome morpholog-
ically and molecularly similar to prion disease. This phenomenon raises the question
whether such antibodies induce infectious prions de novo. Here we exposed cerebellar
organotypic cultured slices (COCS) to the neurotoxic antibody, POM1. We then inoculated
COCS homogenates into tga20 mice, which overexpress PrPC and are commonly utilized
as sensitive indicators of prion infectivity. None of the mice inoculated with COCS-derived
lysates developed any signs of disease, and all mice survived for at least 200 days post-
inoculation. In contrast, all mice inoculated with bona fide prions succumbed to TSE after
55–95 days. Post-mortem analyses did not reveal any signs of prion pathology in mice inoc-
ulated with POM1-COCS lysates. Also, lysates from POM1-exposed COCS were unable to
convert PrP by quaking. Hence, anti-GD antibodies do not catalyze the generation of prion
infectivity. These data indicate that prion replication can be separated from prion toxicity,
and suggest that anti-GD antibodies exert toxicity by acting downstream of prion
replication.
Introduction
Prion diseases are fatal neurodegenerative diseases that rely on the seeded propagation of an
aggregated form of the cellular prion protein PrPC [1]. The aggregated form, denoted PrPSc, is
typically resistant to limited digestion with proteinase K (PK). The pathology triggered by
prion infections, consisting of spongiosis, neuronal loss, astrogliosis, and microglial activation,
is faithfully reproduced by administration of anti-prion antibodies targeting conformational
epitopes on the globular domain (GD) of PrPC [2, 3]. Toxicity requires the long flexible tail
(FT) of PrPC, and antibodies against the octapeptide repeat (OR) domain of the FT prevent the
toxicity of anti-GD antibodies and antagonize neurodegeneration in prion infections [4]. Ther-
apeutic compounds conferring anti-prion protection are frequently effective also against toxic
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anti-prion antibodies, suggesting that GD antibodies and bona fide prions share common effec-
tor pathways [4].
The striking similarities between the consequences of toxic anti-GD antibodies and of prion
infections raised the question whether such antibodiesmight induce the generation of de novo
prions. By distorting the conformation of PrPC, antibodiesmay conceivably catalyze the forma-
tion of higher-order aggregates that would, in turn, act as nucleation sites for the growth of
PrPSc fibers [5]. This question is not only of academic importance, but it may also be of rele-
vance to the biosafety classification of research with such antibodies.We therefore undertook
to clarify whether POM1 induced de novo infectious prions, and if so, whether this might
explain its toxicity. We treated COCShomogenates, which have similar prion propagation effi-
cacies as whole brain homogenates [6], with the toxic anti-prion antibody POM1 and analyzed
them for the presence of de novo prions after passaging into prion-susceptible cells and PrPC-
overexpressing tga20mice [7].
Results
In order to minimize any possible effector functions and off-target effects of the antibodies,
such as complement and Fcγ-binding, we generated single-chain variable fragments (scFv) of
the neurotoxic anti-PrP antibody POM1 (scFvPOM1). PrPC-overexpressing tga20 COCSwere
then treated with either scFvPOM1 (400 nM) or with scFvPOM1 (400 nM) preincubated with
a molar excess of recPrP23-230 (600 nM) for control. This treatment was maintained over 10
days with three medium changes per week; scFvPOM1 was replaced with each medium
change.
NeuN immunofluorescent stainings, which identify neurons, showed widespread neuronal
degeneration in COCS treated with scFvPOM1, but not in COCS treated with antibody that
had been preemptively blocked with recPrP23-230 (Fig 1A). To clarify whether this effect was
induced by the aggregation of PrP, we analyzed pooledCOCS homogenates treated with either
scFvPOM1 (n = 8) or scFvPOM1 + recPrP23-230 (n = 5) for PrPSc, an isoform of PrP that is par-
tially resistant to proteinase K (PK) and is universally employed as a surrogate marker for
prion infectivity (Figs 1B and S1) [8]. Pooled slice homogenates from scFvPOM1-treated
(n = 8) and (scFvPOM1+recPrP23-230))-treated (n = 5) tga20 COCSwere analyzed by Western
blotting and were found to be devoid of PrPSc. In contrast, PK digestion of prion-containing
brain homogenate (RML6 = passage 6 of the RockyMountain Laboratory strain mouse-
adapted scrapie prions), which served as positive control, showed the typical diagnostic shift
towards a smaller PK-resistant core with un-, mono- and diglycosylated PrPSc.
The murine neuroblastoma cell line CAD5 is highly susceptible to prion infection and serves
as a sensitive bioassay for prion propagation [9]. We hence spiked cell culture media of exponen-
tially growing CAD5 cells with RML6 prions, non-infectious brain homogenate (NBH), or
homogenates from COCS that had been exposed to scFvPOM1 or scFvPOM1+recPrP23-230- (6–
12 ng protein of total homogenate in 1 mL of cell culture media). After 4 days of culture, we lysed
the CAD5 cells and assessed PrPSc by Western blotting. No PrPSc was detectable in CAD5 cells
inoculatedwith COCShomogenates exposed to either scFvPOM1 or scFvPOM1+recPrP23-230.
In contrast, RML6 prion-infectedCAD5 cells displayed the typical pattern of PrPSc onWestern
blots (Figs 1C and S2).
To investigate the possible presence of prions in POM1-treated COCS in more detail, we
assessed the prion propagation activity of antibody-treated tga20 COCShomogenates using the
real-time quaking induced conversion assay (RT-QuIC) [10]. The RT-QuIC allows sensitive
detection of PrPSc based on prion-catalyzed cyclic amplification of misfolded PrP. Homoge-
nates of COCS treated with scFvPOM1 or scFvPOM1+recPrP23-230 as well as COCS
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homogenates treated with NBH- and RML6 were spiked into the RT-QuIC reactionmixture
and amplified for 70 hours. Neither scFvPOM1-treated nor (scFvPOM1+recPrP23-230)-treated
COCS homogenates induced de novo PrP aggregate formation in the RT-QuIC assay. In con-
trast, RML6-treated COCS homogenates induced aggregation after an initial lag phase of about
24 hours (Fig 2A).
Fig 1. (A) Chronic treatment of COCS with scFvPOM1 induced profound neurodegeneration. Instead, no neurodegeneration was observed in COCS
exposed to scFvPOM1 pre-incubated with recPrP23-230. *** p<0.001. Scale bar = 500 μm. (B) Pooled slice homogenates of scFvPOM1-treated (n = 8
slices) or (scFvPOM1+ recPrP23-230)-treated tga20 COCS (n = 5 slices) did not show PK-resistant species after digestion as is typically observed in RML6
brain homogenate (n = 1). (C) No PrPSc was observed after inoculation of the highly PrPSc-susceptible cell line CAD5 with pooled scFvPOM1-treated COCS
homogenates. CAD5 cells were successfully infected with RML6 as shown by the typical “diagnostic shift” of PK-digested RML6 with un-, mono- and
diglycosylated PrPSc bands. RML6 brain homogenate served as a positive control (left band pair).
doi:10.1371/journal.pone.0163601.g001
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Fig 2. (A) RT-QuIC analyses failed to reveal de novo PrPSc aggregation when seeded with scFvPOM1 or
(scFvPOM1+recPrP23-230)-treated tga20 COCS homogenates. NBH- and RML6-treated tga20 COCS homogenates
were used as negative and positive controls for prion-catalyzed amplification of aggregated PrP, respectively. RT-QuIC
reactions were performed in quadruplicates for each sample. (B) tga20 mice inoculated with pooled slice homogenates
of scFvPOM1-treated (n = 6 mice) or (scFvPOM1+recPrP23-230)-treated tga20 COCS (n = 6 mice) stayed healthy for at
least 200 days after inoculation. tga20 mice infected at high dose (n = 4 mice) or low dose (n = 5 mice) with RML6
succumbed to prion disease at 55 ± 2 (mean ± s.d., high dose) and 95 ± 5 (high dose) days, respectively.
doi:10.1371/journal.pone.0163601.g002
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The failure to detect PrPSc suggests that exposure to toxic GD ligands does not induce PrP
aggregation. However, the sensitivity of the assays employed is not very high. Moreover, GD
ligands may conceivably induce PK-sensitive PrP aggregates which may still be infectious [11].
Finally, cell-based assays suffer from the differential susceptibility of individual cell lines to spe-
cific prion strains, which is unpredictable and may lead to false-negative results [9].
To overcome these limitations, we tested the transmissibility of pathology from antibody-
treated COCS to PrPC-overexpressing tga20mice that serve as sensitive indicators of prion
infectivity [7, 12]. COCS treated with scFvPOM1 or scFvPOM1+recPrP23-230 (1%, 18 μg total
brain homogenate in 30 μl) were inoculated intracerebrally (i.c.) into tga20mice. In control
experiments (performed non-synchronously with mice of the same genotype and age), tga20
mice were i.c. inoculatedwith RML6 at high dose (1%, 36 μg total brain homogenate, corre-
sponding to 3 x 106 median lethal dose [LD50] units and low dose (0.0001%, 3.6 pg total brain
homogenate, corresponding to 3 x 102 LD50 units). RML6-infectedmice showed the character-
istic clinical signs of terminal prion disease (e.g. progressive ataxia, rolling gait) at 55 ± 2 (high
dose) and 95 ± 5 days (low dose, Fig 2B). tga20mice inoculatedwith homogenates from
scFvPOM1 or scFvPOM1+recPrP23-230 treated COCS, as well as non-inoculated control mice,
did not develop any signs of disease within an observation period of 200 days (Fig 2B).
Immunohistochemical analysis of brain sections from RML6-inoculatedmice showed
prominent and classical signs of prion disease, such as spongiform changes, neuronal cell loss,
astrogliosis, and microglial activation (Fig 3). In contrast, none of these signs were observed in
mice treated with scFvPOM1 COCS homogenate, scFvPOM1+recPrP23-230 COCS homoge-
nate, or non-inoculatedmice (Fig 3). Western blots of brain homogenates from RML6-infected
mice showed the molecular weight shift typical of PrPSc after PK digestion (Figs 4 and S3). No
PrPSc was detected by Western blotting in brain homogenates frommice inoculatedwith
scFvPOM1-COCS, (scFvPOM1+recPrP23-230)-COCS, or NBH.
Discussion
The neurotoxic antibody POM1 mimics the typical prion pathology with spongiform change,
neuronal loss, astrogliosis, and microglial activation, and triggers transcriptomic perturbations
similar to those observed in prion diseases [4]. We have shown that prion toxicity or protection
is dependent on the identity of the PrPC epitopes recognizedby each antibody [2]. Antibodies
targeting the PrPC globular domain are predominantly neurotoxic, whereas those targeting its
flexible tail are largely protective [2]. FT-dependent protection through the OR-binding anti-
body POM2 is independent of prion replication, since it preserves neurons without reducing
the accumulation of PK-resistant PrPSc [4]. PrPC mutants devoid of the octapeptide repeat
domain do not confer POM1 susceptibility to Prnp-deficient COCS, confirming that the FT is
a crucial effector of neurotoxicity [2].
The scrapie prion protein PrPSc is defined through its resistance to enzymatic digestion by
proteases and is commonly used as a surrogate marker for the presence of infectious prions [8],
but it was unclear if, and to what extent, prion mimetics such as the monoclonal antibody
POM1 were able to induce prions. We now report that scFvPOM1 treatment of COCS does
not lead to generation of infectious prions. In view of the pivotal importance of this question,
we addressed it with a set of orthogonal methodologies including a cell bioassay, real-time
quaking induced conversion, and a sensitive bioassay utilizing PrPC-overexpressing transgenic
mice.
The induction of toxicity independent of infectivity suggests the existence of a toxicity-
inducing epitope of PrPC that may be accessible by both neurotoxic antibodies and infectious
Neurotoxic Antibodies against the Prion Protein Do Not Trigger Prion Replication
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prion seeds. The conformational POM1-epitope in the α1-α3 region of PrPC could represent
such a site, since additional monoclonal antibodies other than POM1 targeting residues in
close proximity also induce neurotoxic effects [3].
Because of technological limitations, the docking of infectious PrPSc oligomers to mem-
brane-resident normal PrPC has never been observeddirectly. However, such docking repre-
sents a plausible basis for the phenomenon of prion toxicity. Accordingly, prions damage only
neurons that express PrPC on their surface, whereas Prnp-negative neurons do not experience
degeneration even after chronic, long-term exposure to prions [13]. We therefore speculate
that the docking of POM1 may mimic the process by which prions dock onto PrPC. Conse-
quently, we predict that compounds conferring protection against POM1 may have a high like-
lihood to be protective against infectious prions–a prediction that has been verified
experimentally with a number of compounds [4]. By extension, POM1 toxicity seems to repre-
sent a promising model of prion toxicity that might allow for screening prion-protective com-
pounds without the need of advanced biosafety measures.
In conclusion, our data add to the growing body of evidence that prion protein-mediated
toxicity is independent from prion infectivity, and hence favor a model of prion toxicity in
which toxic prion antibodies operate downstream of prion replication.
Fig 3. Brain sections from terminally sick mice (high dose RML6, lowest row) revealed typical signs of a prion disease such as
spongiform change (H&E), astrogliosis (GFAP), microgliosis (IBA1) and PrPSc deposition (SAF84). None of these features were
observed in tga20 mice inoculated with scFvPOM1-COCS, (scFvPOM1+recPrP23-230)-COCS, or in untreated mice. Scale bar = 50 μm.
doi:10.1371/journal.pone.0163601.g003
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Materials and Methods
Animal experimentation, animal welfare and ethics statement
All animal experiments were conducted in strict accordance with the Rules and Regulations for
the Protection of Animal Rights (Tierschutzgesetz and Tierschutzverordnung) of the Swiss
Bundesamt für Lebensmittelsicherheit und Veterinärwesen BLV. Body weights were measured
weekly. All animal protocols and experiments performedwere specifically approved for this
study by the responsible institutional animal care committee, namely the AnimalWelfare
Committee of the Canton of Zürich (permit numbers 41/2012, 90/2013 and ZH040/2015). All
efforts were made to minimize animal discomfort and suffering.
Animal survival study, inoculation of prions and scFvPOM1-treated
brain tissue
Prion inoculations were performed under isofluorane anesthesia. Monitoring of mice was per-
fomed as describedpreviously [14]. Herein, mice were monitored after prion inoculations
every other day and actions were taken to minimize animal suffering and distress as is laid out
in S1 Table. Diagnosis of scrapie was undertaken according to appropriate clinical criteria,
namely ataxia, limb weakness, front leg paresis and rolling. CO2 inhalation was used to
Fig 4. PK-digestion of brain homogenate from a terminally sick tga20 mouse revealed protease resistance. The residual PrPSc showed
a typical diagnostic shift in its molecular weight. Neither untreated, scFvPOM1-COCS inoculated (n = 3 brain homogenates) nor (scFvPOM1
+recPrP23-230)-COCS inoculated (n = 3 brain homogenates) tga20 mice showed detectable PrPSc.
doi:10.1371/journal.pone.0163601.g004
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euthanize mice on the day of appearance of terminal clinical signs of scrapie (S1 Table). Brains
obtained at necropsy were either snap-frozen for biochemical analysis or fixed in 4% formalin
for histological assessment. The time elapsed from prion inoculation to the terminal stage of
diseasewas defined as incubation time for the survival study. All brain and COCShomogenates
were diluted in 0.32 M sucrose in demineralizedwater before inoculation. 3 months-old tga20
mice were inoculated in the right frontal lobe at 1% (36 μg protein in 30 μL, corresponding to 3
x 106 LD50 units, high dose) and 0.0001% (3.6 ng protein per animal, corresponding to 3 x 102
LD50 units, low dose) of RML6 homogenate, and 1% (18 μg protein in 30 μL) of COCShomoge-
nate. The protein concentrations in brain homogenates used for inoculation are in agreement
with previously reported protein concentrations of infectious and non-infectious brain homog-
enates [15]. No unexpected deaths were observedduring the animal experiments reported.
Cerebellar organotypic slice cultures (COCS)
tga20mice [7] were used for both COCS and prion inoculations. Preparation of COCSwas per-
formed as already described elsewhere [6]. 350 μm thick COCSwere prepared from 9–12 day
old tga20 pups. Antibody exposure was performed after a recovery period of 10–14 days after
slice preparation. For preparation of slice homogenates, COCSwere washed twice with PBS
and homogenized in 0.32 M sucrose solution in demineralizedwater.
Antibodies, recombinant full-length prion protein (recPrP23-230), prion
inoculations and pharmacological treatment of COCS
Single-chain variable fragment antibodies of the IgG antibody POM1 (scFvPOM1) were pro-
duced through purification of inclusion bodies from E. coli on a Ni-NTA column, as reported
before [2]. Bacterial expression of mouse recPrP23-230 was described elsewhere [16, 17]. COCS
were inoculatedwith 100 μg brain homogenate per 10 slices from terminally sick prion-
infected (RML6) or NBH from CD1mice, diluted in 2 mL physiological Grey’s balanced salt
solution as describedbefore [18]. Brain slices were incubated with infectious brain homoge-
nates as free-floating sections for 1 h at 4°C, then washed and 5–10 slices were placed on a
6-well PTFE membrane insert. 10–14 days after slice preparation, antibodies were added with
everymedium change (three times a week).When antibody was given together with recPrP23-
230, addition to slices was preceded by pre-incubation of antibody-recPrPmix on ice for at least
1 hour.
Real-time quaking induced conversion assay
RT-QuIC assays of antibody-treated COCSwere performedusing recombinant hamster prion
protein (HaPrP) as substrate for PrPSc-catalyzed conversion as previously described [10]. The
gene encoding recombinant hamster full-length (23–231) PrP was cloned into the pRSET-A
expression vector (Invitrogen) via the NdeI and EcoRI restriction sites [17]. HaPrP was
expressed in Rosetta2(DE3)pLysS E.coli competent cells in Overnight Express Instant TB
Medium (Merck Novagen) for 26 hours at 30°C and 90 rpm. Briefly, cells were harvested by cen-
trifugation at 17 000 g for 5 min and lysed by repeated freeze-thaw cycles. Cytoplasmic inclusion
bodieswere then washed twice with each 1X and 0.1X BugBuster Protein ExtractionReagent
(Novagen) and solubilized in 8 MGdnHCl (pH 8.0). After another centrifugation step at 17 000
g for 10 min, the supernatant was subjected to an affinity chromatography using Ni2+-nitrilotria-
cetic acid Superflow resin (QIAGEN). The protein was then refolded and purified on column by
running a linear gradient from 100 mMNaH2PO4, 10 mMTris-HCl, 6 M GdnHCl (pH 8.0) to
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100 mMNaH2PO4, 10 mMTris-HCl (pH 8.0) over 3.5 hours. After elution with a linear gradi-
ent to pre-cooled 500 mM imidazol, 100 mMNaH2PO4, 10 mMTris-HCl (pH 6.0), the protein
containing fractions were combined and filtered through a 0.2 μm syringe filter. The purified
protein was dialyzed against 200 mMNaH2PO4 (pH 5.8) and concentrated to a final protein
concentration of 0.6–0.8mg mL-1 prior to storage at -80°C.
For the RT-QuIC assay, recombinant HaPrP was filtered using 100 kDa centrifugal filters
(Pall Nanosep OD100C34) and adjusted to a final concentration of 0.1 mg mL-1 in PBS (pH
7.4) containing 170 mMNaCl, 10 μM EDTA, 10 μM Thioflavin T. RT-QuIC reactions were
seededwith 2 μL scFvPOM1- or (scFvPOM1+recPrP23-230)-treated tga20 COCS homogenates
(0.5 ng μL-1 total protein concentration in N2/PBS) in a total reaction volume of 100 μL.
NBH- and RML6-treated tga20 COCS homogenates were used as negative and positive con-
trols, respectively. All reactions were performed in quadruplicates in black 96-well polystyrene
microplates (Nunc 265301) covered with sealing tape (Nunc 232702). The RT-QuIC reactions
were amplified over a time period of 70 hours at 42°C with alternating cycles of 90 s shaking
at 900 rpm in double orbital mode and 30 s resting using a FLUOstar Omega microplate
reader (BMG Labtech). The amplification of de novo aggregates was followed real-time by
measuring the increase in Thioflavin T fluorescence every 15 min (450/480 nm ex/em filters;
bottom read mode).
In vitro bioassay
In vitro assessment of prion propagation was performedwith subclones of the murine neuro-
blastoma cell line CAD5 as already described [19]. Herein, the cells were exposed to 0.001%
RML6 (12 ng in 1 mL), 0.001% non-infectious brain homogenate (NBH, 11 ng in 1 mL) and
0.001% scFvPOM1- or scFvPOM1+recPrP23-230 COCS homogenate (6 ng in 1 mL). Prions
were allowed to propagate for 3 days followed by a 1:7 split, with three further 3-day growth
periods and 1:7 splits. Cells were harvested, lysed in PBS with 1% Triton-X 100, Complete™
Protease Inhibitor and phosSTOP™ Phosphatase Inhibitor (Roche).
Immunohistochemical stainings and NeuN morphometry
For immunohistochemical stainings, COCSwere rinsed twice in PBS and fixed in 4% parafor-
maldehyde for 2 days at 4°C. COCSwere then washed twice in PBS and incubated in blocking
buffer (0.05% Triton X-100 vol/vol, 0.3% goat serum vol/vol in PBS) for 1 hour at room tem-
perature. Alexa-488 conjugated mouse anti-NeuN antibody (Life Technologies) was diluted at
1.6 μg mL-1 in blocking buffer and incubated for 3 days at 4°C. Slices were washed for 15 min
in PBS followed by a 30 min incubation with DAPI (1 μg mL-1) in PBS at room temperature.
Slices were subsequently washed twice in PBS for 15 minutes and then mounted with fluores-
cent mounting medium (DAKO) on a glass slide. NeuN morphometry of COCSwas under-
taken on images taken on a fluorescent microscope (BX-61, Olympus) at identical exposure
times through custom written scripts for the image analysis software cell^P (Olympus) as
already described [2]. For immunohistochemistry of inoculated brains, formalin-fixed tissues
were processed as described [16]. In brief, antibodies for detection of astrocytes (anti-GFAP;
1:300; DAKO) and microglia (anti-Iba-1; 1:1,000;Wako) as well as for detection of partially
PK-resistant prion protein deposition (anti-PrP SAF-84; 1:200; SPI bio) where applied after the
respective pre-treatment. Sections were developedwith IVIEWDAB Detection kit (Ventana)
and were then counterstained with hematoxylin as described [16]. Afterwards, sections were
screenedmicroscopically (Zeiss Axioskop 2 plus) for astrogliosis, microglia activation and
prion protein deposition by two neuropathologists. Representative images were acquired using
a digital camera (Olympus UC30).
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Protein analysis
Slices in cell culture inserts were washed twice in PBS and further scraped off the membrane
with PBS (10 μL per slice), followed by trituration with a 30G syringe. Protein concentrations
were measured by a bicinchoninic acid-based assay (Pierce™ BCA Protein Assay Kit, Thermo
Fisher). For determination of PrPSc, cell homogenates were digested with 5 μg mL-1, tga20
COCS and C57BL/6 whole brain homogenates were digested with 25 μg mL-1 PK (Roche) at a
final volume of 20 μL in PBS for 30 minutes at 37°C. tga20 whole brain homogenates were
digested with 50 μg mL-1 PK at a final volume of 20 μL in PBS for 45 minutes at 37°C. Loading
buffer was added and samples were boiled at 95°C for 5 minutes to deactivate PK. Equal sample
volumes were loaded on Nu-PAGE Bis/Tris precast gels (Life Technologies) andWestern blot-
ting was performed using the monoclonal anti-PrP antibody POM1 as described elsewhere [4].
Statistical analyses
Unless mentioned otherwise, unpaired, two-tailed student’s T-test was used for comparing
data from two groups and one-way ANOVA with Dunnett’s post-hoc test for comparing mul-
tiple groups. All data is given as mean ± standard deviation. Statistical analysis and data visuali-
zation was done using GraphPad Prism 6 (GraphPad).
Supporting Information
S1 Fig. Uncropped and unmodifiedWestern blot of fig 1B with sizemarkers.
(TIF)
S2 Fig. Uncropped and unmodifiedWestern blot of fig 1C with sizemarkers.
(TIF)
S3 Fig. Uncropped and unmodifiedWestern blot of fig 4 with sizemarkers.
(TIF)
S1 Table. Clinical assessment and scoring of tga20 mice inoculatedwith RML6 according
to [14].
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